- About Us
- Nano-Social Network
- Nano Consulting
- My Account
August 13th, 2007
Personalized-medicine startup Nanosphere filed for a $100 million IPO Monday, but an analyst said the move could be a prelude to a merger with one of its larger rivals.
Nanosphere, based in Northbrook, Illinois, makes a system to perform molecular diagnostic tests. Earlier this year Nanosphere applied for U.S. Food and Drug Administration approval of tests to gauge a person's risk of blood clots and how a patient metabolizes the anti-blood clot medicine warfarin, sold under the brand name Coumadin.
The company also is developing tests for cancer, cystic fibrosis gene mutation, herpes viral infection, and cardiovascular disease risk and diagnosis.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
In-cell molecular sieve from protein crystal February 14th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017
Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017